{"abstract": "Under the terms of the deal, Bristol-Myers Squibb will pay $26 a share, 163 percent above Inhibitex\u2019s closing price on Friday.", "web_url": "https://dealbook.nytimes.com/2012/01/07/bristol-myers-to-buy-inhibitex-for-2-5-billion/", "snippet": "Under the terms of the deal, Bristol-Myers Squibb will pay $26 a share, 163 percent above Inhibitex\u2019s closing price on Friday.", "lead_paragraph": "Bristol-Myers Squibb agreed late on Saturday to buy Inhibitex, a maker of a hepatitis C treatment, for about $2.5 billion in cash, as major drug companies seek to bolster their pipelines with more profitable specialty products.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Bristol-Myers to Acquire Inhibitex for $2.5 Billion", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Bristol Myers Squibb Company", "rank": 1, "major": "N"}], "pub_date": "2012-01-08T04:48:37+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/32f04af6-2205-5910-a379-5d24d4c82c6e", "word_count": 319, "uri": "nyt://article/32f04af6-2205-5910-a379-5d24d4c82c6e"}